APA (7th ed.) Citation

LE, A., JP, B., Y, L., RM, S., L, B., A, Z., . . . M, S. (2026). Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics. Blood neoplasia, 3(2), 100201. https://doi.org/10.1016/j.bneo.2026.100201

Chicago Style (17th ed.) Citation

LE, Aguirre, et al. "Comparative Effectiveness of HMA with Venetoclax Vs Intensive Chemotherapy in AML with Very High-risk Cytogenetics." Blood Neoplasia 3, no. 2 (2026): 100201. https://doi.org/10.1016/j.bneo.2026.100201.

MLA (9th ed.) Citation

LE, Aguirre, et al. "Comparative Effectiveness of HMA with Venetoclax Vs Intensive Chemotherapy in AML with Very High-risk Cytogenetics." Blood Neoplasia, vol. 3, no. 2, 2026, p. 100201, https://doi.org/10.1016/j.bneo.2026.100201.